X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (461) 461
Book Review (96) 96
Publication (49) 49
Book Chapter (10) 10
Newsletter (5) 5
Book / eBook (4) 4
Conference Proceeding (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (446) 446
humans (429) 429
oncology (146) 146
female (138) 138
animals (132) 132
male (132) 132
lymphomas (124) 124
cancer (116) 116
lymphoma (110) 110
hematology (109) 109
middle aged (103) 103
adult (89) 89
aged (84) 84
apoptosis (75) 75
cell line, tumor (72) 72
immunohistochemistry (71) 71
pathology (69) 69
lymphoma - enzymology (66) 66
lymphoma, b-cell - enzymology (65) 65
mice (65) 65
lymphoma, non-hodgkin - enzymology (63) 63
lymphoma, follicular - enzymology (53) 53
b-lymphocytes - enzymology (52) 52
expression (52) 52
abridged index medicus (51) 51
hemic and lymphatic diseases (51) 51
lymphoma, large b-cell, diffuse - enzymology (51) 51
gene expression (50) 50
activation (49) 49
cell biology (48) 48
aged, 80 and over (47) 47
prognosis (47) 47
genetic aspects (46) 46
mutation (46) 46
antineoplastic agents - therapeutic use (45) 45
follicular lymphoma (45) 45
research (45) 45
chronic lymphocytic-leukemia (44) 44
lymphoma, b-cell - pathology (44) 44
leukemia (43) 43
non-hodgkin's lymphomas (43) 43
proteins (43) 43
non-hodgkins-lymphoma (41) 41
care and treatment (40) 40
lymphoma - pathology (38) 38
lymphoma, non-hodgkin - pathology (38) 38
analysis (36) 36
antineoplastic agents - pharmacology (36) 36
medicine (36) 36
research article (36) 36
tumors (36) 36
apoptosis - drug effects (35) 35
b-cell lymphoma (35) 35
pharmacology & pharmacy (35) 35
immunology (34) 34
multidisciplinary sciences (34) 34
article (33) 33
biochemistry & molecular biology (33) 33
gene (32) 32
kinases (32) 32
lymphoma, b-cell - genetics (32) 32
survival (32) 32
adolescent (31) 31
gene expression regulation, neoplastic (31) 31
lymphoma, large b-cell, diffuse - pathology (31) 31
protein kinase inhibitors - therapeutic use (31) 31
lymphoma, follicular - pathology (30) 30
neoplasms - enzymology (30) 30
treatment outcome (30) 30
protein-tyrosine kinases - metabolism (29) 29
acute lymphoblastic-leukemia (28) 28
chemotherapy (28) 28
health aspects (28) 28
neoplasms - drug therapy (28) 28
phosphorylation (28) 28
physiological aspects (28) 28
signal transduction (28) 28
b cells (27) 27
lymphoma, follicular - genetics (27) 27
science (27) 27
enzymes (26) 26
leukemia, lymphocytic, chronic, b-cell - enzymology (26) 26
lymphoma, large b-cell, diffuse - genetics (26) 26
child (25) 25
lymphoma, non-hodgkin - drug therapy (25) 25
cell cycle (24) 24
cell proliferation (24) 24
immune system diseases (24) 24
lymphoma - genetics (24) 24
medicine, research & experimental (24) 24
multiple-myeloma (24) 24
nf-kappa-b (24) 24
phenotype (24) 24
b-lymphocytes - pathology (23) 23
blotting, western (23) 23
cell proliferation - drug effects (23) 23
hodgkin disease - enzymology (23) 23
methylation (23) 23
protein kinase inhibitors - pharmacology (23) 23
protein-tyrosine kinases - antagonists & inhibitors (23) 23
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 08/2011, Volume 476, Issue 7360, pp. 298 - 303
Journal Article
Nature, ISSN 0028-0836, 12/2012, Volume 491, Issue 7427, pp. 108 - 112
In eukaryotes, post-translational modification of histones is critical for regulation of chromatin structure and gene expression. EZH2 is the catalytic subunit... 
LYSINE 27 | METHYLATION | MULTIDISCIPLINARY SCIENCES | B-CELL LYMPHOMAS | GENES | HISTONE METHYLTRANSFERASE EZH2 | H3K27 | HYPERTRIMETHYLATION | SOMATIC MUTATIONS | HUMAN CANCER | Polycomb Repressive Complex 2 - antagonists & inhibitors | Neoplasm Transplantation | Gene Silencing - drug effects | Lymphoma, Follicular - drug therapy | Polycomb Repressive Complex 2 - genetics | Histones - chemistry | Humans | Transcriptional Activation - drug effects | Transplantation, Heterologous | Histone-Lysine N-Methyltransferase - antagonists & inhibitors | Lymphoma, Follicular - genetics | Indoles - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Repressor Proteins - metabolism | Histone-Lysine N-Methyltransferase - genetics | Repressor Proteins - chemistry | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Lymphoma, Follicular - pathology | Lymphoma, Large B-Cell, Diffuse - enzymology | Mutation - genetics | Enhancer of Zeste Homolog 2 Protein | Animals | Histone-Lysine N-Methyltransferase - metabolism | Methylation - drug effects | Cell Line, Tumor | Indoles - therapeutic use | Lymphoma, Follicular - enzymology | Cell Proliferation - drug effects | Mice | Pyridones - therapeutic use | Histones - metabolism | Polycomb Repressive Complex 2 - metabolism | Lymphoma, Large B-Cell, Diffuse - genetics | Pyridones - pharmacology | Gene mutations | Methyltransferases | Physiological aspects | Lymphomas | Genetic aspects | Research | Health aspects | Risk factors | Care and treatment | Proteins | Cell growth | Cytotoxicity | Mutation | Gene expression | Laboratory animals | Tumors | Apoptosis | Index Medicus
Journal Article
The Journal of Immunology, ISSN 0022-1767, 10/2007, Volume 179, Issue 7, pp. 4929 - 4938
Journal Article
Blood, ISSN 0006-4971, 12/2006, Volume 108, Issue 13, pp. 4156 - 4162
The mammalian target of rapamycin (mTOR) is emerging as a promising target for antitumor therapy. However, the mechanism that contributes to its regulation in... 
MAMMALIAN TARGET | HUMAN NEUTROPHILS | PHOSPHOLIPASE-D | LEUKEMIA B-CELLS | TUBEROUS SCLEROSIS | PROTEIN-TYROSINE KINASE | FC-GAMMA-RIIA | HEMATOLOGY | ANTIGEN RECEPTOR | SIGNAL-TRANSDUCTION PATHWAY | CANCER-THERAPY | Protein Kinases - metabolism | Burkitt Lymphoma - enzymology | RNA, Small Interfering - genetics | Lymph Nodes - pathology | Lymphoma, Follicular - drug therapy | Protein-Tyrosine Kinases - metabolism | Humans | Lymphoma, Mantle-Cell - pathology | Intracellular Signaling Peptides and Proteins - metabolism | Phosphatidylinositol 3-Kinases - metabolism | Stilbenes - pharmacology | Neoplasm Proteins - metabolism | Burkitt Lymphoma - pathology | Lymphoma, B-Cell - enzymology | Palatine Tonsil - metabolism | Syk Kinase | Burkitt Lymphoma - drug therapy | Lymphoma, B-Cell - drug therapy | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Lymphoma, Follicular - pathology | RNA, Small Interfering - pharmacology | Lymph Nodes - metabolism | Lymphoma, Mantle-Cell - drug therapy | Enzyme Activation - drug effects | Phospholipase D - metabolism | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Leukemia, Lymphocytic, Chronic, B-Cell - enzymology | Signal Transduction - drug effects | Lymphoma, Mantle-Cell - enzymology | Lymphoma, B-Cell - pathology | Cell Line, Tumor | Lymphoma, Follicular - enzymology | TOR Serine-Threonine Kinases | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Palatine Tonsil - enzymology | Index Medicus | Abridged Index Medicus
Journal Article
Nature, ISSN 0028-0836, 03/2011, Volume 471, Issue 7337, pp. 189 - 195
B-cell non-Hodgkin's lymphoma comprises biologically and clinically distinct diseases the pathogenesis of which is associated with genetic lesions affecting... 
CBP | RUBINSTEIN-TAYBI SYNDROME | HISTONE ACETYLTRANSFERASES | ACETYLATION | P300 | MULTIDISCIPLINARY SCIENCES | CREB-BINDING-PROTEIN | CYCLE ARREST | ACUTE MYELOID-LEUKEMIA | TRANSCRIPTIONAL COACTIVATOR | P53 | Histone Acetyltransferases - deficiency | Recurrence | Acetyltransferases - metabolism | Histone Acetyltransferases - chemistry | Humans | E1A-Associated p300 Protein - genetics | Gene Expression Regulation, Neoplastic | Histone Acetyltransferases - genetics | CREB-Binding Protein - chemistry | E1A-Associated p300 Protein - metabolism | Lymphoma, B-Cell - genetics | Acetyltransferases - genetics | Mutation, Missense - genetics | CREB-Binding Protein - genetics | DNA-Binding Proteins - metabolism | CREB-Binding Protein - metabolism | Lymphoma, Follicular - genetics | Acetyltransferases - deficiency | Base Sequence | Histone Acetyltransferases - metabolism | Lymphoma, B-Cell - enzymology | HEK293 Cells | Acetylation | CREB-Binding Protein - deficiency | Lymphoma, Large B-Cell, Diffuse - pathology | Lymphoma, Follicular - pathology | Cells, Cultured | E1A-Associated p300 Protein - chemistry | Lymphoma, Large B-Cell, Diffuse - enzymology | Tumor Suppressor Protein p53 - metabolism | Protein Structure, Tertiary - genetics | Mutation - genetics | Acetyl Coenzyme A - metabolism | Acetyltransferases - chemistry | Animals | Lymphoma, B-Cell - pathology | Polymorphism, Single Nucleotide - genetics | Protein Binding | Lymphoma, Follicular - enzymology | Mice | E1A-Associated p300 Protein - deficiency | Lymphoma, Large B-Cell, Diffuse - genetics | Proto-Oncogene Proteins c-bcl-6 | Sequence Deletion - genetics | Lymphomas | Genetic aspects | B cells | Gene mutations | Health aspects | Abnormalities | Proteins | Congenital diseases | Pathogenesis | Genes | Cell cycle | Genomes | Genetic engineering | Mutation | Binding sites | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 1, pp. 44 - 50
Purpose Aurora A kinase (AAK) is overexpressed in aggressive lymphomas and can correlate with more histologically aggressive forms of disease. We therefore... 
SURVIVAL | IN-VITRO | ADVANCED SOLID TUMORS | RITUXIMAB PLUS CYCLOPHOSPHAMIDE | ONCOLOGY | SYNTHETIC LETHAL | MYC | VINCRISTINE | MLN8237 | LEUKEMIA CELLS | NF-KAPPA-B | Burkitt Lymphoma - enzymology | Recurrence | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Aurora Kinase A - antagonists & inhibitors | Lymphoma, T-Cell - enzymology | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Molecular Targeted Therapy - methods | Burkitt Lymphoma - drug therapy | Protein Kinase Inhibitors - pharmacokinetics | Azepines - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Drug Administration Schedule | Pyrimidines - administration & dosage | Lymphoma, Large B-Cell, Diffuse - enzymology | Lymphoma, Mantle-Cell - drug therapy | Treatment Outcome | Azepines - therapeutic use | Protein Kinase Inhibitors - administration & dosage | Lymphoma, T-Cell - drug therapy | Lymphoma, Mantle-Cell - enzymology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Lymphoma, Follicular - enzymology | Aged | Azepines - pharmacokinetics | Azepines - administration & dosage | Index Medicus | Hema13 | ORIGINAL REPORTS
Journal Article
Cancer Science, ISSN 1347-9032, 11/2016, Volume 107, Issue 11, pp. 1687 - 1695
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/2010, Volume 107, Issue 29, pp. 12747 - 12754
Human tumors contain populations of both cancerous and host immune cells whose malignant signaling interactions may define each patient's disease trajectory.... 
T lymphocytes | Phosphorylation | Health outcomes | B lymphocytes | B cell lymphoma | T cell lymphoma | Stem cells | Lymphoma | Tumors | Cancer | Follicular lymphoma | Signaling profile | B-cell receptor | Phospho-flow cytometry | SURVIVAL | ACTIVATION | follicular lymphoma | signaling profile | CYCLOPHOSPHAMIDE | MULTIDISCIPLINARY SCIENCES | PHASE-III | IMMUNOGLOBULIN | phospho-flow cytometry | KAPPA-B | CANCER STEM-CELLS | HUMAN FOLLICULAR LYMPHOMA | ANTIGEN-RECEPTOR | NON-HODGKINS-LYMPHOMA | Lymphoma, Follicular - therapy | Reproducibility of Results | Prognosis | Lymphoma, Follicular - pathology | Humans | Phosphoprotein Phosphatases - metabolism | Disease Progression | Lymphocyte Subsets - immunology | Receptors, Antigen, B-Cell - immunology | Signal Transduction - immunology | Extracellular Space - metabolism | Models, Immunological | Phenotype | B-Lymphocytes - immunology | CD40 Antigens - metabolism | Lymphocytes, Tumor-Infiltrating - pathology | Lymphoma, Follicular - immunology | Survival Analysis | Lymphoma, Follicular - enzymology | B-Lymphocytes - pathology | Enzyme Activation | Lymphocyte Subsets - pathology | Lymphocytes, Tumor-Infiltrating - immunology | Development and progression | B cells | Cytokines | Health aspects | Flow cytometry | Antigens | Immunology | Medical prognosis | Lymphomas | Gene expression | Cells | Index Medicus | CD40 antigen | Cell survival | Tumor-infiltrating lymphocytes | Tumor cells | Lymphocytes T | Cell interactions | Cytometry | Interleukin 7 | Chemotherapy | Lymphocytes B | Microenvironments | Biological Sciences
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 2015, Volume 6, Issue 9, pp. 6544 - 6552
Serine-threonine kinase CK2 is highly expressed and pivotal for survival and proliferation in multiple myeloma, chronic lymphocytic leukemia and mantle cell... 
CX-4945 | Non-Hodgkin Lymphoma | CK2 | B-cell | CANCER-CELLS | INDUCED APOPTOSIS | PHOSPHORYLATION | CLASSIFICATION | DEATH | CELL BIOLOGY | PATHOGENESIS | PROSURVIVAL | SELECTIVE INHIBITOR | ONCOLOGY | CHRONIC LYMPHOCYTIC-LEUKEMIA | Burkitt Lymphoma - enzymology | Phosphorylation | Humans | Gene Expression Regulation, Neoplastic | Gene Expression Profiling | Casein Kinase II - genetics | RNA, Messenger - metabolism | Burkitt Lymphoma - pathology | Dose-Response Relationship, Drug | Lymphoma, Follicular - genetics | Burkitt Lymphoma - genetics | Antineoplastic Agents - pharmacology | Retrospective Studies | B-Lymphocytes - pathology | Cell Survival - drug effects | B-Lymphocytes - enzymology | Lymphoma, Large B-Cell, Diffuse - pathology | Signal Transduction | Lymphoma, Follicular - pathology | Casein Kinase II - antagonists & inhibitors | Cell Cycle Proteins - metabolism | Lymphoma, Large B-Cell, Diffuse - enzymology | Blotting, Western | Gene Expression Regulation, Enzymologic | B-Lymphocytes - drug effects | Chaperonins - metabolism | Transcription Factor RelA - metabolism | Cell Line, Tumor | Lymphoma, Follicular - enzymology | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Lymphoma, Large B-Cell, Diffuse - genetics | Casein Kinase II - metabolism | Naphthyridines - pharmacology | Index Medicus
Journal Article